Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amsterdam Molecular Therapeutics has signed an agreement with Digna Biotech and the Center for the Study of Applied Medicine, for the development of AAV-mediated insulin-like growth factor I to treat late-stage liver cirrhosis.
Subscribe to our email newsletter
The agreement stems from the exclusive license to Amsterdam Molecular Therapeutics (AMT) from Digna Biotech to commercialize all gene therapy products resulting from the R&D activities performed at the Center for the Study of Applied Medicine (CIMA) at the University of Navarra, Spain. The insulin-like growth factor (IGF-1) program is the first initiated under that agreement.
Ronald Lorijn, CEO of AMT, said: “We are very pleased with our agreement with CIMA, which gives us access to programs that are already well-advanced and that have tremendous potential. AMT is fully dedicated and equipped to add this new program to its product pipeline and plans to start the necessary pre-clinical studies including a full toxicology program next year.”